Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
N/A N=410 MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making
Menopause · Premenopause · Postmenopause
Primary: Perceived Quality of Information — 4.1; 3.7 score on a scale — p=<.001
N/A N=360 Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition
Menopausal Syndrome
Primary: Change From Baseline in Menopause Rating Scale Total Score — 6.3; 4.5 units on a scale — p=0.05
Phase 2 N=24 A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Menopause · Multiple Sclerosis
Primary: Hot Flash Related Daily Interference Scale (HFRDIS) Score — 4; 9 score on a scale
N/A N=1,036,294 A Study to Learn More About the Menopausal Hormone Therapies in Korea
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
Phase 3 N=943 Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4 — -3.9; -5.6; -6.0; -6.0 Number of events — p=<0.01
Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…
N/A N=90 Electro-acupuncture for Menopausal Transition Symptoms
Menopause
Primary: Change of Average 24 h Hot Flash Score From Baseline — -2.29; -0.71; -0.78; -0.71 Scores on a scale
Phase 1 N=20 A Treatment Study for Premenstrual Syndrome (PMS)
Premenstrual Syndrome · Menstruation Disturbances
Primary: Mean Beck Depression Inventory Score — 2.6; 3.0; 5.3; 3.6 score on a scale
Phase 3 N=570 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12. — 10.83; 10.90; -4.13; -2.71 Hot flashes per day — p=<0.0001
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 3 N=614 Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
Postmenopausal Symptoms
Primary: Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12. — 11.79; 11.65; -4.71; -3.36 Hot flash per day — p=<0.0001
Phase 2 N=73 A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Major Depressive Disorder · Menopause · Perimenopause
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 26.2; 27.0; 15.7; 15.2 units on a scale — p=0.29
N/A N=6 Effects of Estrogen Deficiency on Energy Expenditure
Obesity
Primary: Brown Adipose Tissue Activity — 3.9; 4.0 Standard uptake value (SUV) — p=0.84
N/A N=401 Measuring Quality of Decisions About Treatment of Menopausal Symptoms
Menopause
Primary: Menopause Knowledge — 51.3; 55.8 Percentage (0-100%) — p=0.01
Phase 4 N=157 Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women
Nocturnal Vasomotor Symptoms
Primary: Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes — -19.54; -20.55; -15.99 Awakenings
N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
Phase 3 N=1,845 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
Menopause
Primary: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) — -40.6; -35.1; -33.6; -38.9 weekly hot flushes — p=<0.001
Phase 3 N=735 Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Vasomotor Symptoms · Hot Flashes
Primary: Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) — -54.515; -54.125; -44.389; -30.020 Hot Flushes per week — p=<0.0001
Phase 2 N=190 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Vasomotor Symptoms (VMS)
Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects
Phase 2 N=169 Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
Menopause
Primary: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) — 73.5; 69.5; 70.4; 67.9 Number of MSVS/2 weeks — p=0.5730